Blood Coagulatio n & Anemia

References

1. Johnson-Wimbley, Terri D and David Y Graham. “Diagnosis and management of iron deficiency anemia in the 21st century” Therapeutic advances in gastroenterology vol. 4,3 (2011): 177-84.

2. Mayeux, Richard. “Biomarkers: potential uses and limitations” NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics vol. 1,2 (2004): 182-8.

3. Lundby, Carsten et al. “Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume” Journal of physiology vol. 578,Pt 1 (2006): 309-14.

4. Jacobs K, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985;313:806–810. doi: 10.1038/313806a0

5. Thomsen JJ, Rentsch RL, Robach P, Calbet JA, Boushel R, Rasmussen P, et al. Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity. Eur J Appl Physiol. 2007;101(4):481–6. doi: 10.1007/s00421-007-0522-8

6. Thurnham DI, McCabe LD, Haldar S, Wieringa FT, Northrop-Clewes CA,McCabe GP. Adjusting plasma ferritin concentrations to remove the effects of subclinical inflammation in the assessment of iron deficiency: a meta-analysis. Am.J.Clin.Nutr. 2010; 92: 546–555. 10.3945/ajcn.2010.29284

7. Klim, S M et al. “Fibrinogen - A Practical and Cost Efficient Biomarker for Detecting Periprosthetic Joint Infection” Scientific reports vol. 8,1 8802. 11 Jun. 2018, doi:10.1038/s41598-018-27198-3

8. Bothwell TH, Charlton RW, Cook JD, Finch CA. Iron Metabolism in Man. Oxford: Blackwell Scientific Publications; 1979

9. Cook JD, Flowers CH, Skikne BS. The quantitative assessment of body iron. Blood. 2003;101(9):3359–3364.

10. Plug T and Meijers JC. Structure-function relationships in thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost 2016; 14: 633-644.

11. Yaoita N, Satoh K, Satoh T, Sugimura K, Tatebe S, Yamamoto S, Aoki T, Miura M, Miyata S, Kawamura T, Horiuchi H, Fukumoto Y and Shimokawa H. Thrombin-activatable fibrinolysis inhibitor in chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol 2016; 36: 1293-1301.

12. Arpaia G, Carpenedo M, Verga M, et al. D-dimer before chemotherapy might predict venous thromboembolism. Blood Coagul Fibrinolysis 2009;20(3):170-175.

13. Ferroni P, Martini F, Portarena I, et al. Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients. Clin Lung Cancer 2012;13(6):482-487.

14. Cosmi B, Legnani C, Cini M, Guazzaloca G, Palareti G. The role of D-dimer and residual venous obstruction in recurrence of venous thromboembolism after anticoagulation withdrawal in cancer patients. Haematologica 2005;90(5):713-715.